All MRNA Content

Moderna, Inc (MRNA) Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

April 7, 20261 min read

Moderna, Inc (MRNA) Q4 2025 Earnings Call Transcript

Moderna, Inc (NASDAQ: MRNA) Q4 2025 Earnings Call dated Feb. 13, 2026 Corporate Participants: Lavina Talukdar — Head of Investor...

March 10, 202645 min read

Moderna, Inc (MRNA) Sec Form 8K

Moderna, Inc (NASDAQ: MRNA) Sec Form 8K

March 6, 20261 min read

Moderna, Inc (MRNA) Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

March 3, 20261 min read

Moderna, Inc (MRNA) European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

February 27, 20261 min read

Moderna, Inc (MRNA) Sec Form 10K

Moderna, Inc (NASDAQ: MRNA) Sec Form 10K

February 22, 20261 min read

Moderna, Inc (MRNA) Barclays 28th Annual Global Healthcare Conference

Moderna, Inc (NASDAQ: MRNA) FY 2026 Corporate Conference

February 19, 20261 min read

Moderna, Inc (MRNA) TD Cowen 46th Annual Healthcare Conference

Moderna, Inc (NASDAQ: MRNA) FY 2026 Corporate Conference

February 19, 20261 min read

Moderna, Inc (MRNA) Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

February 18, 20261 min read

Moderna, Inc (MRNA) Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

February 17, 20261 min read